Introduction
============

Disturbances in synaptic function are a key feature of many neurological, neurodevelopmental and psychiatric disorders \['synaptopathies' ([@awy046-B4])\]. Genetic studies have implicated mutations in genes encoding synaptic proteins in autism spectrum disorders, developmental delay, intellectual disability and epilepsy. Mechanistic studies have identified synaptic deficits in model systems and relevant behavioural phenotypes in mouse models ([@awy046-B4]).

One poorly understood synaptopathy is a spectrum of disorders caused by mutations in the *STXBP1* (syntaxin-binding protein 1, encoding the presynaptic protein Munc18-1), together referred to as STXBP1-encephalopathies, one of the early infantile epileptic encephalopathies (EIEE4, OMIM \#612164). STXBP1-encephalopathies are caused by *de novo* heterozygous missense or truncating mutations or micro-deletions, first reported by [@awy046-B61], and include intellectual disability, epilepsy, autism spectrum disorders, and involuntary movements (spasms and jerks) ([@awy046-B28]; [@awy046-B11]). A meta-analysis of 147 patients with STXBP1-encephalopathy reported in literature up to 2016 found that all patients had intellectual disability, 95% had epilepsy and around 20% were diagnosed with autism ([@awy046-B67]). In patients with STXBP1-encephalopathy, epilepsy is characterized by early onset of tonic spasms, often immediately after birth, and intractable seizures with multifocal epileptic activity on EEG ([@awy046-B61]).

To help understand how STXBP1/Munc18-1 mutations lead to such complex and diverse pathology, the availability of cellular and *in vivo* models is critical. Null mutant nematodes ([@awy046-B3]), flies ([@awy046-B32]), mice ([@awy046-B73]) and zebrafish ([@awy046-B25]) have been studied, but more precise *in vivo* models, that mimic haploinsufficiency, have not been described so far. Inactivation of two copies of one *stxbp1* gene in fish, a species that underwent an additional genome duplication, might be considered such a model ([@awy046-B25]), but functional diversification of duplicated genes since the duplication event, still make this situation different from inactivation of one copy of the only *STXBP1* gene in mammals. Several studies have tested single *STXBP1* human disease associated mutations in cell-free experiments or in cultured neurons (i.e. C180Y, V84D, M443R, G544D and R367X heterozygous mutations). These studies proposed different pathogenic mechanisms: altered affinity for its binding partner, syntaxin-1 ([@awy046-B61]; [@awy046-B82]), impaired protein stability ([@awy046-B61]), or a propensity of protein to aggregate ([@awy046-B7]). Finally, dominant negative effects cannot be excluded. Hence, different working mechanisms have been proposed to explain STXBP1-encephalopathy, even for the same mutations, but no *in vivo* models have been described.

The aim of this study was to systematically compare *STXBP1* patient mutations at the cellular level, to characterize impairments in their cellular function and to generate mouse models for STXBP1-encephalopathy. Seven human disease-causing mutations were introduced into the *STXBP1* sequence and expressed on a *Stxbp1* null background to assess basic protein function and on a heterozygous background to mimic the human patient situation. Protein stability of these variants was assessed in HEK293 cells and primary neurons. Four *Stxbp1*^+/−^ mouse models were generated to model *Stxbp1* haploinsufficiency on different genomic backgrounds or to test selective haploinsufficiency in GABAergic cells. The translational value of these models was tested using EEG, a battery of cognitive and other behavioural tests. Our data suggest that cellular Munc18-1 instability is the probable explanation for *Stxbp1* haploinsufficiency. Seizures, tonic spasms and EEG-abnormalities observed in humans are all recapitulated in *Stxbp1*^+/−^ mice and were suppressed by the antiepileptic drug levetiracetam. Cognitive deficits and hyperactivity were also observed in these mouse models, but not autism related social deficits. Our data suggest protein instability, haploinsufficiency and cortical imbalanced excitability as the underlying mechanism of the observed phenotype implicating *Stxbp1*^+/−^ mice as a valid model.

Materials and methods
=====================

Study design
------------

This study was designed to investigate the effects of different *STXBP1* mutations found in patients on neuronal function and to generate and characterize mouse models for STXBP1-encephalopathy with respect to construct-, face-, and predictive validity. The study is a three-layered analysis: *in silico*, *in vitro* and *in vivo*. The study followed the ARRIVE guidelines (<https://www.nc3rs.org.uk/arrive-guidelines>). We systematically compare public resources of human exome sequencing data and analyse the incidence of *STXBP1* mutations. *In vitro* experiments were performed in the cultures obtained from *Stxbp1*^+/−^ and *Stxbp1*^−/−^ mice bred on a C57BL/6J background. Number of animals used for *in vitro* experiments was \<5 mice per group. Number of replicates for *in vitro* experiments is indicated in the figures. Sample size for the behavioural experiment was between 7 and 13 male mice per group. When the several batches of the same line and same genotype were tested, data were matched. Total number of mice used in the behavioural study is indicated in the 'Animals' section and the exact number of mice per group is indicated in the figures. During the behavioural experiments, the mouse identification number, but not the genotype of the mouse, was available to the researcher. The mouse identification number was connected with the right genotype in the database. Analysis of behavioural data was performed blinded to genotype and two persons independently analysed EEG/electrocorticography (ECoG) and video-monitoring data. Before any analysis was performed, behavioural data were examined for outliers \[\>3 times the standard deviation (SD) from the strain mean\] and outlier data were removed. The number of outliers per group is indicated in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Generation of lentiviral particles
----------------------------------

Generation of lentiviral constructs driven by the human synapsin promoter, generation of virus stocks, and neuron infections were performed as published ([@awy046-B79]). *STXBP1* human disease variants were generated using Quickchange (Stratagene) and sequence verified. For expression in *Stxbp1* heterozygote neurons *Stxbp1* wild-type and mutants were cloned into lenti vector pSyn-Munc18-T2A-CreEGFP in which synapsin drives expression in neurons of Munc18-1 and of CreEGFP via the cleavage-peptide sequence T2A. Viral particles were titrated in HEK293 (ATCC) cells and equal titres were used to infect *Stxbp1* null mutant or heterozygote neurons at *in vitro* Day 0.

Cell culture and electrophysiology
----------------------------------

For quantification of Munc18-1 levels, embryonic cortical neurons from *Stxbp1* null mutant mice (embryonic Day 18) were grown on glass coverslips (150 000 cells/12 wells) coated with poly-[l]{.smallcaps}-ornithine (Sigma, P4957; 5 μg/ml) and laminin (Sigma, L2020; 2.5 μg/ml). Autaptic neuronal culture and electrophysiological recordings were performed as described ([@awy046-B68]; [@awy046-B79]). Briefly, cortices were dissected in Hank's balanced salt solution (HBSS; Sigma, H9394) supplemented with 10 mM HEPES and digested with 0.25% trypsin (Life Technologies, 15090-046) at 37°C for 20 min. After trituration, cells were plated in a 12-well plate at a density of 1000 cells/well for *Stxbp1*^+/−^ neurons and 6000 cells/well for *Stxbp1* null neurons on top of pre-grown rat glia islands on 18 mm coverslips. The 6-fold higher density for *Stxbp1* null neurons was necessary to ensure similar neuronal density as it was for *Stxbp1*^+/−^ neurons in mature cultures 2 weeks later, due to cell death of *Stxbp1* null neurons before viral expression of Munc18 (variants) rescues cell viability. Cultures were grown in Neurobasal® supplemented with 2% B27 (Life Technologies, 17504-044), 18 mM HEPES (Life Technologies 15630-056), 0.5 mM GlutaMAX™ (Life Technologies 35050-038) and 0.1% penicillin/streptomycin (Life Technologies, 15140-122). Cells were whole-cell voltage clamped at −70 mV using Axopatch 200A. Recordings were performed on *in vitro* Days 14--17 with borosilicate glass pipettes (2.5--4 mΩ) containing (in mM): 125 K^+^-gluconate, 10 NaCl, 4.6 MgCl~2~, 4 K2-ATP, 1 EGTA, 15 creatine phosphate, 20 U/ml phosphocreatine kinase (pH 7.30, 300 mOsm). Action potentials were induced by 0.5 ms depolarizing steps to +30 mV. Digidata 1322A and Clampex 9.0 were used for signal acquisition. All recordings were performed at room temperature. Custom-made MatLab routines, Clampfit 9.0 and Minianalysis software were used for offline analysis. Readily releasable pool size was estimated by back extrapolation of cumulative excitatory postsynaptic current (EPSC) charge during a 40 Hz 100 action potential train as in [@awy046-B48].

Immunocytochemistry and confocal microscopy
-------------------------------------------

Cultures were fixed at *in vitro* Day 14 with 4% formaldehyde, permeabilized with 0.5% Triton™ X-100 and stained with primary antibodies for 1 h at room temperature, washed with phosphate-buffered saline (PBS) and stained for 2 h at room temperature with Alexa conjugated secondary antibodies (1:1000, Invitrogen). Primary antibodies were used at the following concentrations: Munc18-1 (SySy 116.003; 1:1000), MAP2 (Abcam ab5392, 1:1000), VAMP2 (SySy 104 211, 1:2000), Syntaxin-1 (not commercial polyclonal I379), Synapsin (not commercial polyclonal E028). Coverslips were mounted with DABCO-Mowiol® (Sigma, 81381) and examined on a Zeiss LSM510 confocal microscope. Images were acquired with a 40× oil objective (N.A. 1.3) and 0.7× mechanical zoom and analysed in MATLAB with SynD ([@awy046-B64]). Somatic protein levels were quantified by placing six 10 × 10-pixel regions of interest in the cell soma. Synaptic protein levels were quantified by placing single regions of interest on all VAMP2-positive synapses as described in [@awy046-B64].

Pharmacological treatments in heterologous cells and neurons
------------------------------------------------------------

For protein stability assays, HEK293 cells were infected with lentiviral particles expressing piCreEGFP2aMunc18 wild-type or EIEE mutants in Opti-MEM® (Life Technologies; 31985-070). After 2 days, cells were replated in Dulbecco's modified Eagle medium with 10% foetal bovine serum. After 8 h, cycloheximide treatments were performed by adding cycloheximide (100 µg/ml; Sigma) or dimethyl sulphoxide (DMSO) as control after which cells were lysed in SDS sample buffer after 0, 6, 12, 24 and 30 h. Munc18-1 levels were assessed after SDS-PAGE and transfer to nitrocellulose membranes using Munc18-1 rabbit polyclonal (not commercial polyclonal 2701, 1:1000), mouse monoclonal GFP (eBioscience; 1:1000) and mouse monoclonal actin (Chemicon; 1:10000) primary antibodies and IRDye® 680LT-anti mouse and/or IRDye® 800CW-anti rabbit as secondary antibody (both 1:5000). Blots were scanned on an Odyssey CLx Imaging system (LI-COR) and quantified with Image Studio Lite software (LI-COR Biotechnology, Germany). For protease inhibition experiments, cells were incubated for 15 h with 100 µg/ml cycloheximide and 10 µM MG132 (BioConnect; sc-201270), 25 µM Leupeptin (Sigma; L2884) or 1 µM Pepstatin A (Sigma; P5318) or DMSO (1:500) after which cells were processed as described above. To test protein stability of Munc18-1 wild-type and EIEE mutants in neurons, *in vitro* Day 0 *Stxbp1* null cortical neurons were first infected in suspension with pLentiM18wtEGFP to rescue cell lethality of *Stxbp1* null neurons and incubated for 1.5 h at 37°C; 5% CO~2~ after which neurons were plated at a density of 300 000 cells per well on poly-[l]{.smallcaps}-ornithine/laminin coated 6-well plates. At *in vitro* Day 4, cells were infected with piCreEGFP2aM18 (wild-type or EIEE mutants) and after 10 days (*in vitro* Day 14) 100 µg/ml cycloheximide was added and cells were lysed after 0, 12, 24 and 36 h, after which cells were processed as described above.

Animals
-------

All animals were kept in standard husbandry conditions. Animals aged 8--10 weeks were separately housed on sawdust in the standard Makrolon type II cages on a 12-h light-dark cycle (light was on at 7:00 h). Food and water were available *ad libitum*. Behavioural experiments were performed on male mice aged between 8 and 12 weeks. All experiments were approved by the local animal research committee and complied with the European Council Directive (86/609/EEC).

Nine batches of congenic BL6 male mice, four batches of conditional null mice, where a single copy of a floxed allele was excised using Cre expression (*Stxbp1^cre^*^/^*^+^*), and one batch of reverse 129Sv mice were used. The total number of animals used was 181 for congenic BL6 line, 62 for the *Stxbp1^cre^*^/^*^+^* line and 24 for reverse 129Sv balanced number of mice between genotypes (*Stxbp1^+^*^/^*^+^* and *Stxbp1*^+/−^ mice). One batch of 28 *Gad2-Stxbp1^cre^*^/^*^+^* mice was generated in which a high mortality was observed, and for ethical reasons breeding of these mice was discontinued. Distribution of mice per batch and per experiment is shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

High-density mouse genotyping
-----------------------------

To determine the extent of residual 129S1Sv/J genome sequence flanking gene-targeted regions on a BL6 background, we ran a high-density mouse genotyping array. The 'MegaMUGA' array (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751547/>) contains 77 808 strain-informative single nucleotide polymorphism (SNP) markers, allowing the direct mapping of coordinates of residual 129S1Sv/J sequence. These coordinates were entered into the Genes and Marker Query on the Mouse Genome Informatics database (<http://www.informatics.jax.org/marker/>) to identify protein coding genes within the flanking 129S1Sv/J sequence.

Next, we used a recently developed web tool: 'Me-PaMuFind-It' (<http://me-pamufind-it.org/>) to generate a list of potential genes from the 129S1Sv/J genome that contained mutations, and remained after 20 generations of backcrossing, called passenger mutations ([@awy046-B71]). It should be noted, however, that our congenic BL6 line was backcrossed for 40 generations and the flanking gene region was smaller than one predicted for the 20th generation by the web tool. Finally, comparing the list of protein coding genes within flanking gene region revealed by high-density genomic analysis with the list of potential passenger mutations obtained from web tool, we predicted passenger mutations in the samples that potentially influenced the phenotypic outcome in mutant mouse.

Immunohistochemistry
--------------------

*Stxbp1^cre^* ^/^ *^+^*, congenic BL6 *Stxbp1*^+/−^ mice and controls (*n* = 4, 5 and 5, respectively) were sacrificed by cervical dislocation. Brains were fixed in 4% PFA (paraformaldehyde) and cryoprotected in a 30% sucrose solution overnight. Brains were blocked in the coronal plane, frozen on dry ice, and sectioned at 50 µm on a cryostat. Coronal brain sections were stained with c-Fos primary antibody (Santa Cruz, sc-52; 1:800/1:500). After overnight incubation, sections were incubated with biotinylated goat anti-rabbit secondary antibody (\#65-6140, Invitrogen; 1:400). The sections were then incubated in avidin-biotin peroxidase complex (Vectastain ABC, Vector Laboratories; 1:800) and peroxidase labelling was visualized by DAB/nickel substrate working solution (DAB Peroxidase Substrate, SK-4100; Vector Laboratories). Images were obtained using a Leica light microscope (×10 magnification) and number of c-Fos positive cells was counted using ImageJ software. A detailed description of the protocol and analysis can be found in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

Video monitoring
----------------

Heterozygous mice and their controls from all three lines: conditional *Stxbp1* line, congenic BL6 *Stxbp1* line and reverse 129Sv *Stxbp1* line were individually housed and their behaviour was recorded during 4--9 h. Detection of spontaneous abnormal behavioural events was done off-line by two researchers unaware of the mice genotype. Preliminary analysis revealed two types of behaviours observed in all *Stxbp1*^+/−^ mice, but not in their controls. These two behavioural events were described as twitch and jump. A twitch was defined as a sudden, myoclonic jerk of the animal's body from resting state (apparent sleep) that did not cause the mouse to wake ([Fig. 5](#awy046-F5){ref-type="fig"}A and [Supplementary Video 1](#sup2){ref-type="supplementary-material"}). Jumps were differentiated from twitches by a change in the position of the mouse in the cage. In contrast to twitches, jumps were followed by activity ([Fig. 5](#awy046-F5){ref-type="fig"}B and [Supplementary Video 2](#sup3){ref-type="supplementary-material"}) and sometimes accompanied by a Straub tail reaction. In total 42 mice were analysed (more details of batches in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Simultaneous radiotelemetric EEG-video monitoring and levetiracetam treatment
-----------------------------------------------------------------------------

ECoG transmitters (ETA-F10; specification: [https://www.datasci.com/products/implantable-telemetry/mouse-(miniature)/eta-f10)](https://www.datasci.com/products/implantable-telemetry/mouse-(miniature) were implanted under deep anaesthesia induced and maintained by isoflurane. The recording electrode was positioned above the motor cortex (2.2 mm anterior, 1 mm lateral) and the ground electrode was positioned above the cerebellum (6 mm posterior, 1 mm lateral) using the stainless screws. The transmitter was placed subcutaneously (s.c.) in the abdominal pocket. All animals received pre- and postoperative analgesic treatment (buprenorphine, 0.005 mg/kg, s.c.). Simultaneous ECoG recording and video-monitoring of the animals were performed during at least 24 h started after 7 days recovery period.

For intrahippocampal EEG recordings mice were analysed with a telemetric EEG/video-monitoring system (TL11M2-EET, DSI) as described before ([@awy046-B56]). Briefly, intraperitoneally (i.p.) narcotized male mice \[16 mg/kg xylazine (xylariem, Ecuphar) and 100 mg/kg ketamine i.p. (ketamine 10%, WDT)\] were implanted with depth EEG electrodes at an age of 70 days with subcutaneous transmitter placement on the right abdominal side. Depth electrodes were positioned in left and right hippocampal CA1 (−2 AP, ±1.4 ML, 1.3 DV) ([@awy046-B100]). Reference electrodes were placed with a stainless screw in contact with the cerebellar cortex of the simple lobe at the midline (−6 AP, 0 ML, 0 DV). All implanted mice received analgesic treatment before and once per day for 3 days post-operation (5 mg/kg ketoprofen, subcutaneously; Gabrilen®, MIBE). Simultaneous EEG and video monitoring was carried out for 16 days. Visual inspection of recordings revealed no significant differences between days. Thus, EEG and video monitoring over a period of 24 h was analysed in detail.

A group of congenic BL6 *Sxbp1*^+/−^ mice with cortically implanted ECoG transmitters was subjected to treatment with antiepileptic drug, levetiracetam (Sigma Aldrich). Treatment started after a recovery period with intraperitoneal injection of saline (0.9% sodium chloride) at the beginning of the light phase. One day after saline injection, mice were injected with levetiracetam (50 mg/kg, i.p.) and treatment continued once daily for 5 days (levetiracetam 50 mg/kg, i.p.). ECoG/video monitoring was performed for at least 6 h, beginning 60 min after saline injection, first and fifth levetiracetam injections. Levetiracetam dose, pretreatment time and duration of assessment of drug effects were based on previous studies ([@awy046-B44]; [@awy046-B16]).

Two observers, unaware of the mouse genotype, independently analysed EEG and ECoG signal and video records. Visual inspection of electrographic signal revealed spike-wave discharges with narrow peak frequency ∼7 Hz as the potential pathological electrographic activity. Probability of concurrence of spike-wave discharges longer than 1.5 s and behavioural epileptic-like events (previously described twitches and jumps) within ±10 s was analysed by calculating probability of coincidence, a concurrence of the events without apparent causal connection. Probability of 0.05 was taken as the borderline for the connection. In total 15 mice were analysed. More details about surgery and analysis can be found in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

Visual analysis of the ECoG signal was complemented with an automated detection of potentially pathological events using the Event Classifier application in Neuroarchiver software (Open Source Instruments) during 24 h of recording. Video and ECoG recordings were used to select abnormal ECoG events (spike-wave discharges) that were accompanied with behavioural manifestation. The selected events were classified based on several metrics using Event Classifier and included into the library of potentially pathological events ([Supplementary Fig. 5A](#sup1){ref-type="supplementary-material"}). The generated library allowed fast, automatic identification of similar abnormal electrographic events. Detailed description of event sorting is available at: <http://www.opensourceinstruments.com/Electronics/A3018/Seizure_Detection.html#Similarity%20of%20Events>.

Behavioural phenotyping
-----------------------

Behavioural phenotyping of all *Stxbp1* mice started with the assessment of the spontaneous behaviour in an automated home-cage environment (PhenoTyper model 3000, Noldus Information Technology). This system allows the assessment of several aspects of animal behaviour over a period of a few days, without human interference. Spontaneous behaviour was automatically monitored for 3 days in the PhenoTyper ([@awy046-B46]; [@awy046-B43]). The observation of spontaneous behaviour was followed by the assessment of avoidance learning using Shelter task ([@awy046-B46]) or discrimination and reversal learning using the CognitionWall task in the same automated home-cage ([@awy046-B57]).

After testing in the PhenoTyper, the test battery was performed on 26 congenic BL6 *Stxbp1* mice (Batch 1) and 24 *Stxbp1^cre^*^/^*^+^* mice (Batch 1) aged between 8 and 10 weeks old in order to test muscle strength, anxiety, learning and memory. Mice were weighed and acclimatized to their new housing for 1 week prior to testing. All tests were performed during the light phase, starting from the least stressful: novelty induced hypophagia, grip strength meter, elevated plus maze, open field, dark-light box, rotarod, and Barnes maze. Briefly, novelty induced hypophagia test was performed to assess anxiety-related behaviour, by measuring time to eat the cracker in the new cage. At least 1 day later, grip strength meter was performed to assess the muscle strength by measuring the force applied in grasping a pull bar. Additionally, three anxiety-related paradigms were performed: elevated plus maze, open field, and dark-light box; these tests are based on the natural aversion of mice for open and/or bright spaces. The anxiety-related parameters in these tests were: latency, time spent, and number of visits to the anxiety-related compartments (open arms, centre zone, bright compartment). Accelerating rotarod was performed to assess motor coordination and motor learning in mice; the parameter monitored was maximum rotation per minute (rpm) reached in each trial. The assessment of spatial learning and memory and reversal learning was done using the Barnes maze test. Mice were trained to choose one of the 24 holes in the Barnes maze as the escape hole. Latency to find the escape hole and distance travelled to the escape were measured as the parameters of learning. Memory was assessed by the probe trial when the escape hole was removed and hole visits per octant was measured. Reversal learning was checked by relocating the escape hole to the diametrically opposite position.

New batches of congenic BL6 and *Stxbp1^cre^*^/^*^+^* mice were used to perform additional tests that needed to be done separately because of possible interference with other tests: congenic *Stxbp1* BL6 mice, from Batches 2 to 6, were used for modified Barnes maze, 5-choice serial reaction time test, three-chamber test, Shelter task, CognitionWall; and Batch 2 from the *Stxbp1^cre^*^/^*^+^* line was used to perform three-chamber test and CognitionWall test. The modified Barnes maze test is designed to improve assessment of spatial learning by avoiding development of serial strategy. The maze contains 44 holes divided into three rings, instead of 24 holes in one perimeter. The training procedure and parameters analysed were similar to the Barnes maze test. The various aspects of attention and impulsivity were assessed using the 5-choice serial reaction time test by calculating response accuracy, percentage of premature responses and correct response latency. The three-chamber test was applied for assaying sociability and preference for social novelty in mice. The parameters analysed were time spent in the mouse/novel mouse zone.

The reverse *Stxbp1* 129Sv mice (24 mice in total) were tested in the similar test battery as *Stxbp1^cre^*^/^*^+^* and congenic BL6 mice. However, before the beginning of the behavioural experiments, reverse 129Sv animals were recorded in their home-cage for assessment of epileptic-like activity. In addition, considering very low activity of the 129Sv strain, the rotarod and three-chamber test were not performed and instead of the Barnes maze test, the Morris water maze was done. A detailed description of the behavioural experiment is provided in the [Supplementary material](#sup1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

All statistical analyses were performed using IBM SPSS statistic 20 (IBM corporation, Armonk, NY, USA). The effect of genetic background and genotype were assessed using two-way ANOVA, or repeated measure ANOVA. When the assessment of genetic background effect was not applicable, the genotype differences were compared using parametric tests (*t*-test, ANOVA, repeated-measures ANOVA) whenever normality and homoscedasticity criteria were met. Otherwise, non-parametric tests were performed (Kruskal-Wallis, Mann-Whitney U-test). To assess genotype effect in CognitionWall DL/RL task, the log rank test was performed for two Kaplan-Meier survival curves. An error probability level of *P \<*0.05 was accepted as statistically significant throughout the study of the classical behavioural tests. For all given level of analysis of PhenoTyper spontaneous behaviour data, statistical analysis was based on estimated false discovery rate (FDR), *P*-values were corrected by minimum positive FDR with a threshold set at 5% ([@awy046-B74]).

Results
=======

Human genomics data imply a crucial role of STXBP1 in normal development
------------------------------------------------------------------------

We performed an *in silico* analysis of publicly available genomics data on *STXBP1*, especially from the Exome Aggregation Consortium (ExAC, [@awy046-B41]) and at <http://gnomad.broadinstitute.org>. No loss-of-function mutations were observed in over 60 000 humans (pLI = 1, [@awy046-B41]), while, based on its size, 25.5 mutations are predicted. The clinically-observed, heterozygous, and pathogenic mutations in *STXBP1*: C180Y, V84D, M443R, G544D, R367X, T574P, and C522R, ([Fig. 1](#awy046-F1){ref-type="fig"}A) are all ultra-rare ([@awy046-B41]), and were not observed in over 140 000 human whole exomes and genomes at <http://gnomad.broadinstitute.org>. Our recent analysis of all available whole exome sequence data implicated 288 genes, and *STXBP1* was the only gene implicated in all neurodevelopmental disorders studied: developmental delay (*q* = 4 × 10^−17^), epilepsy (*q* = 3 × 10^−8^), intellectual disability (*q* = 0.008), and autism (*q* = 0.10, [@awy046-B52]). These data indicate that STXBP1 is exceptionally intolerant to loss-of-function mutations and therefore predicted to be exceptionally important in normal human development and for brain function. Heterozygous mutations certainly occur, but the phenotypic consequences are highly adverse with strong negative selection pressure.

![**Morphological and electrophysiological characteristics of dissociated hippocampal neurons expressing the human disease variants in *Stxbp1* null mouse neurons.** (**A**) Schematic overview of some of the previously discovered STXBP1 truncations, deletions and missense mutations in human patients showing the seven mutations tested in colour-coded boxes. (**B**) Dissociated cortical neurons were stained for Munc18-1, dendritic marker MAP2 and synaptic marker synaptobrevin (VAMP). Examples represent *Stxbp1* null neurons expressing wild-type Munc18-1 (WT), C180Y or M433R. (**C--G**) Morphological and synaptic characteristics of Munc18-1 wild-type neurons, *Stxbp1*^+/−^ neurons and null mutant neurons expressing one of the human disease variants: (**C**) mean synapse density calculated as the ratio of synapse number and total dendritic length. (**D**) Mean soma Munc18-1 level. (**E**) Mean synaptic Munc18-1 level. (**F** and **G**) Mean somatic and synaptic syntaxin-1 level. (**H**) Example traces of evoked release from wild-type neurons, *Stxbp1* null neurons expressing C180Y and M433R upon a single action potential stimulation. (**I**) Mean EPSC amplitude expressed as the ratio of the wild-type value. (**J**) Paired-pulse ratio (calculated as the ratio of second EPSC and first EPSC) depending on the pulse interval. (**K**) Frequency of spontaneous release normalized to the wild-type values. (**L**). Amplitude of spontaneous release normalized to the wild-type values. (**M**) Example traces of spontaneous release in *Stxbp1* null neurons expressing Munc18-1 wild-type, C180Y or M433R human variants. (**N**) The size of the readily releasable pool derived from back extrapolation of cumulative total charge released during 40 Hz train, 100 APs. The number of analysed cells is indicated in the bars. \**P \<*0.05, \*\**P \<*0.01, \*\*\**P \<*0.001 versus infected wild-type control. Explanation of statistical analysis is provided in the [Supplementary material](#sup1){ref-type="supplementary-material"}. mEPSC = mini excitatory postsynaptic current; RRP = readily releasable pool.](awy046f1){#awy046-F1}

Expression of human disease variants produces diverse phenotypes consistent with haploinsufficiency
---------------------------------------------------------------------------------------------------

To assess the functional impact of *STXBP1* mutations found in human patients, we generated seven patient mutations in the Munc18-1 protein ([Fig. 1](#awy046-F1){ref-type="fig"}A) and expressed each of these in null mutant mouse neurons in culture with wild-type Munc18-1 protein as control ([Fig. 1](#awy046-F1){ref-type="fig"}B and [Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). In this way, neurons rely exclusively on one of these variants and the loss of basic protein function can be compared quantitatively to wild-type Munc18-1 protein for each of the seven selected mutations. In these initial experiments, we used microdot cultures, where single neurons grow on islands of rat astrocytes. This reduced and standardized preparation allows quantitative comparisons between neurons expressing different variants for many morphological and functional parameters ([@awy046-B79]; [@awy046-B64]; [@awy046-B63]). Subsequently, we tested a selection of these variants in neurons carrying a single copy of the *Stxbp1* gene to model the situation in patients (see below).

The most firmly established molecular function of Munc18-1 is to prepare synaptic vesicles for release in the presynaptic nerve terminal (reviewed in [@awy046-B70]). Consequently, in the absence of Munc18-1, neurons have no synaptic activity, not even spontaneous activity ([@awy046-B73]) and die within a few days *in vitro* and *in vivo* ([@awy046-B73]; [@awy046-B34]; [@awy046-B63]). Expression of five human variants in *Stxbp1* null mutant neurons rescued neuronal viability: C180Y, M433R, G544D, T574P and C522R ([Fig. 1](#awy046-F1){ref-type="fig"}C). However, few null mutant neurons expressing R388X survived and no neurons expressing V84D survived. Neurons expressing one of the five variants that rescued viability, also formed synapses and had a normal dendritic length ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}); however, neurons expressing M443R and G544D variants had lower synaptic density compared to the wild-type viral expression (*P* \< 0.001, *P* = 0.005, respectively; [Fig. 1](#awy046-F1){ref-type="fig"}C). These data show that in a reduced neuronal model system, three of the selected Munc18-1 variants behave like wild-type Munc18-1 protein when analysed for survival and morphological parameters, but two variants, R388X and V84D, did not rescue viability, and two show mild impairments in synapse formation or maintenance. Hence, Munc18-1 variants that produce similar clinical features, behave rather differently under conditions where neurons rely solely on a given variant.

One of the proposed effects of point mutations in Munc18-1 is a reduced stability of the mutant protein ([@awy046-B61]; [@awy046-B67]). Therefore we analysed cellular protein levels for all five variants that rescued viability. Expression of wild-type Munc18-1 in null mutant neurons using lentiviral vectors produced ∼2-fold higher expression levels in the soma as compared to endogenous Munc18-1 in wild-type neurons ([Fig. 1](#awy046-F1){ref-type="fig"}D). However, expression of C180Y, T574P and C522R using the same viral infection produced significantly lower protein levels in the soma relative to wild-type viral expression (*P =*0.003, *P =*0.017 and *P =*0.010, respectively; [Fig. 1](#awy046-F1){ref-type="fig"}D). Somatic expression levels of the two mutants that had lower synaptic density, M443R and G544D ([Fig. 1](#awy046-F1){ref-type="fig"}C), were similar to over-expression of wild-type Munc18-1 (M443R) or at least as high as uninfected wild-type neurons (G544D; [Fig. 1](#awy046-F1){ref-type="fig"}D).

Targeting of Munc18-1 variants to the nerve terminal was assessed by quantifying immunoreactivity in synapses using staining for the synapse marker synapsin as a mask. The synaptic Munc18-1 levels of all five variants were significantly lower than wild-type viral expression \[*F*(5,125) = 29.77, *P \<*0.001; [Fig. 1](#awy046-F1){ref-type="fig"}E\]. Loss of Munc18-1 expression is known to reduce the cellular level of the SNARE protein syntaxin-1 ([@awy046-B75]; [@awy046-B69]). The syntaxin-1 expression level was slightly reduced in the soma for C180Y and G544D variants ([Fig. 1](#awy046-F1){ref-type="fig"}F) and more profoundly in the synapse of neurons expressing M443R and G544D variants ([Fig. 1](#awy046-F1){ref-type="fig"}G), while the synaptic level of another presynaptic protein, VAMP/synaptobrevin 2 was unaltered for all variants ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). These data suggest that the Munc18-1 variants C180Y, T574P and C522R have reduced stability and that the remaining M443R and G544D are impaired in synaptic targeting of both Munc18-1 and syntaxin-1. This may explain the reduced synapse density for these two variants ([Fig. 1](#awy046-F1){ref-type="fig"}C). However, the synaptic Munc18-1 level is comparable to heterozygous synapses and might therefore be sufficient to support basal synaptic transmission ([@awy046-B68]).

We assessed synaptic transmission using patch clamp recordings of *Stxbp1* null mutant neurons expressing one of the four Munc18-1 variants tested above (C180Y, M443R, T574P, C522R) and compared these to neurons expressing wild-type Munc18-1. Null mutant neurons expressing C180Y, T574P or C522R showed normal evoked responses, but neurons expressing M443R showed a 50% reduced response ([Fig. 1](#awy046-F1){ref-type="fig"}H and I). C180Y and C522R showed similar paired pulse plasticity, but M443R and T574P showed increased paired pulse plasticity, suggesting reduced release probability ([Fig. 1](#awy046-F1){ref-type="fig"}J). Null mutant neurons expressing the M443R variant also exhibited a severely reduced frequency of spontaneous synaptic events ([Fig. 1](#awy046-F1){ref-type="fig"}K and M). While evoked synaptic transmission was normal in C180Y expressing null mutant neurons, the spontaneous event frequency was reduced ([Fig. 1](#awy046-F1){ref-type="fig"}K and M). Neurons expressing T574P and C522R variants did not show significantly reduced spontaneous frequency ([Fig. 1](#awy046-F1){ref-type="fig"}K and M). In all cases the amplitude of spontaneous events was normal ([Fig. 1](#awy046-F1){ref-type="fig"}L), confirming the presynaptic origin of these phenotypes. Finally, to assess the size of the readily releasable pool and vesicle recruitment rates, we plotted the synaptic responses to trains of action potentials cumulatively ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). We observed different recruitment rates and pool sizes among the four variants tested, but no significant differences ([Fig. 1](#awy046-F1){ref-type="fig"}N). Taken together, these morphological and functional data on the null mutant background show that different variants of the Munc18-1 protein found in patients have retained basic protein function to different extents, with most affected V84D \> R388X \> M443R and G544D \> C180Y \> T574P and C522R. Given the fact that these mutations all produce similar clinical features, haploinsufficiency becomes the most plausible explanation for STXBP1-encephalopathy pathogenesis.

Expression of human disease variants in heterozygous neurons supports normal synaptic transmission
--------------------------------------------------------------------------------------------------

To model the situation in patients as precisely as possible, we expressed the same seven variants tested above on the null background, now in *Stxbp1* heterozygous neurons. Hence, in this case, neurons express both wild-type Munc18-1 (from a single endogenous allele) and one of the variants, as is the case in patients. Under these conditions, all variants supported normal synaptic development ([Fig. 2](#awy046-F2){ref-type="fig"}A and B), also neurons expressing V84D or R388X, which were shown not to rescue viability when expressed on the null background ([Fig. 1](#awy046-F1){ref-type="fig"}). Analysis of Munc18-1 levels confirmed that heterozygous neurons have ∼50% lower Munc18-1 expression levels in soma and synapses as compared to wild-type neurons ([Fig. 1](#awy046-F1){ref-type="fig"}D and E), in line with previous analyses ([@awy046-B68]). Expression of none of the Munc18-1 variants produced a significant increase in somatic or synaptic Munc18-1 levels. Both somatic and synaptic Munc18-1 levels remained below that of wild-type neurons (*P \<*0.001 and *P \<*0.001 for all variants compared to wild-type viral expression, [Fig. 2](#awy046-F2){ref-type="fig"}C and D), while the synaptic VAMP/synaptobrevin 2 level was normal in all cases \[*F*(6,173) = 2.03, *P =*0.064; [Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}\]. Together these data provide further support for the conclusion that all seven Munc18-1 variants tested have a reduced cellular stability. The fact that synaptogenesis is normal in heterozygous neurons expressing the most severely affected mutants V84D and R388X, argues against dominant negative effects.

![**Morphological and electrophysiological characteristics of dissociated hippocampal neurons expressing the human disease variants in *Stxbp1*^+/−^ mouse neurons.** (**A**) Dissociated cortical neurons were stained for Munc18-1 and synaptic marker synaptobrevin (VAMP). Examples represent *Stxbp1*^+/−^ neurons expressing wild-type Munc18-1 (WT), C180Y or M433R human variants. (**B--D**) Morphological and synaptic characteristics of *Stxbp1*^+/−^ neurons expressing wild-type Munc18-1 or one of the human disease variants: (**B**) mean synapse density: calculated as the ratio of synapse number and total dendritic length. (**C** and **D**) Mean somatic and synaptic Munc18-1 level. (**E**) Example traces of evoked release upon a single action potential stimulation from *Stxbp1*^+/−^ neurons expressing wild-type Munc18-1, C180Y, M433R, V84D, G544D or R388X human variants. (**F**) Mean EPSC amplitude expressed as the ratio of the infected wild-type values. (**G**) Paired-pulse ratio (second EPSC/first EPSC) depending on the pulse interval. (**H**) Readily releasable pool estimate derived from back-extrapolation of cumulative total charge released during 40 Hz train, 100 APs (**I**) Frequency of spontaneous release expressed as the ratio of infected wild-type values. (**J**) Amplitude of spontaneous release expressed as the ratio of infected wild-type values. (**K**) Example traces of spontaneous release in *Stxbp1*^+/−^ neurons expressing wild-type Munc18-1, C180Y, M433R, G544D, R388X or V84D human variants. The number of analysed cells is indicated in the bars. \*\*\**P \<*0.001 versus infected wild-type control. mEPSC = mini excitatory postsynaptic current; RRP = readily releasable pool.](awy046f2){#awy046-F2}

Heterozygous neurons expressing each of the seven Munc18-1 variants showed normal synaptic transmission. Evoked responses \[*F*(5,262) = 1.58, *P =*0.166; [Fig. 2](#awy046-F2){ref-type="fig"}E and F\], paired pulse plasticity ([Fig. 2](#awy046-F2){ref-type="fig"}G) and frequency and amplitude of spontaneous events \[*F*(5,240) = 1.64, *P =*0.149 and *F*(5,240) = 0.83, *P =*0.526, respectively; [Fig. 2](#awy046-F2){ref-type="fig"}I--K\] were all similar between heterozygous neurons expressing wild-type Munc18-1 or one of the variants found in patients. Cumulative plots of the total charge during action potential trains revealed no differences in vesicle recruitment rate or the size of the readily releasable pool \[*F*(5,237) = 1.06, *P =*0.383; [Fig. 2](#awy046-F2){ref-type="fig"}H and [Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). Hence, while the different Munc18-1 variants have retained basic protein function to a different extent, all of them support normal synaptic transmission when combined with a single wild-type allele, as is the case in patients. Taken together, these data show that expression of different Munc18-1 variants with different basic protein function and cellular stability, do not lead to differences in synaptic transmission on the time scale of the *in vitro* experiments performed here in the presence of one wild-type Munc18-1 allele.

Reduced protein stability for all Munc18-1 variants found in patients
---------------------------------------------------------------------

Analyses of the expression of Munc18-1 variants in *Stxbp1* null and heterozygous neurons produced evidence for reduced protein stability for most variants. We tested this more systematically by expression of C180Y, M443R, C522R and T574P variants in heterologous cells (HEK293) as a part of a bicistronic expression cassette where each of the variants is expressed as a single mRNA of a variant fused to GFP, separated by a 2A sequence ([@awy046-B60]). Upon translation, the single mRNA generates two separate proteins in a 1:1 ratio by ribosome skipping. In this way, GFP intensity can be used as an in-cell control across all variants and was used to normalize expression levels of the variants. All mutants showed a distribution similar to wild-type protein, albeit much weaker, with no signs of accumulation in specific compartments ([Fig. 3](#awy046-F3){ref-type="fig"}A and [Supplementary Fig. 3](#sup1){ref-type="supplementary-material"}). All four Munc18-1 variants and the wild-type protein showed complete cleavage of the 2A sequence and no signs of read-through ([Fig. 3](#awy046-F3){ref-type="fig"}B). An ∼80% lower level was detected for all mutants, as compared to the wild-type protein ([Fig. 3](#awy046-F3){ref-type="fig"}A and B). Hence, all Munc18-1 variants found in patients show a severe reduction in protein stability in heterologous cells.

![**Cellular stability of wild-type and human disease variants of Munc18-1 in HEK293 cells and neurons.** (**A**) Immunochemistry of HEK293 cells infected with wild-type Munc18-1 (WT), C180Y, M443R, C522R and T574P constructs stained for Munc18-1, EGFP and Golgi marker (GM130). (**B**) Normalized Munc18-1 levels in HEK293 cells after viral infection with wild-type, C180Y, M443R, C522R and T574P constructs. The *inset* shows representative western blot of HEK293 cells after viral infection; *n =*5, 5, 5, 2 and 2, respectively. (**C**) Western blot analysis of Munc18-1 protein levels 0, 6, 12, 24 and 30 h after block of protein synthesis with cycloheximide for HEK293 cells infected with wild-type, C180Y, M433R, C522R or T574P constructs. The infection with wild-type construct was used as a control for all performed western blot analysis. (**D**) Quantitative analysis of the Munc18-1 protein expression from western blots in HEK cells represented in **C**. (**E**) Western blot analysis of Munc18-1 protein levels 0, 12, 24 and 36 h after block of protein synthesis with cycloheximide for wild-type, C180Y, M433R, C522R or T574P constructs in *Stxbp1* null neurons. The infection with wild-type construct was used as a control for all performed western blot analysis. (**F**) Quantitative analysis of the Munc18-1 protein expression from western blots in neurons represented in **E**. (**G--I**) Normalized Munc18-1 protein levels from three constructs expressed in HEK cells treated with MG132, Leupeptin or Pepstatin; *n* = 3, 2 and 2, respectively.](awy046f3){#awy046-F3}

To further document this reduced stability, we performed pulse-chase experiments in HEK cells and primary mouse neurons by inhibiting protein synthesis with 100 µg/ml cycloheximide at t = 0 and quantifying the cellular Munc18-1 levels at different time points afterwards using immunoprecipitation of the denatured protein, which is almost 100% efficient for this protein/antibody combination ([@awy046-B12]). Both in HEK293 cells ([Fig. 3](#awy046-F3){ref-type="fig"}C and D) and in primary mouse neurons ([Fig. 3](#awy046-F3){ref-type="fig"}E and F), the major difference in initial protein level between wild-type Munc18-1 and all the variants found in patients was confirmed. The half-life in heterologous cells was much shorter (10-fold decrease in 30 h) than in primary mouse neurons (2-fold over the same period; *cf.*[Fig. 3](#awy046-F3){ref-type="fig"}D and F). To identify the cellular pathways responsible, we tested inhibition of the proteasome system using 10 µM MG132 or the lysosomal system using 25 µM Leupeptin/1 µM Pepstatin A for two selected Munc18-1 variants. No evidence for the involvement of these two cellular pathways was observed ([Fig. 3](#awy046-F3){ref-type="fig"}G--I). These data show that all Munc18-1 variants found in patients have a severely reduced cellular stability, especially in heterologous cells, but also in primary neurons. We found no evidence for dominant negative phenotypes and we did not identify specific locations or pathways in the cell that could be linked to the impaired stability of these mutants. Taken together, these data provide strong support for haploinsufficiency as the best explanation for the observed clinical phenotype.

Generation and genomic analysis of *Stxbp1*^+/−^ mouse lines
------------------------------------------------------------

The *in vitro* data support a haploinsufficiency model to explain STXBP1 pathogenesis and not other explanations (e.g. dominant negative effects). Therefore, we studied *Stxbp1* heterozygous mice (*Stxbp1*^+/−^) as a model for haploinsufficiency in STXBP1-encephalopathy.

Four *Stxbp1*^+/−^ mouse lines were generated ([Fig. 4](#awy046-F4){ref-type="fig"}A--D): (i) a *Stxbp1^cre^*^/^*^+^* line where one copy of the gene was flanked by loxP sites and subsequently deleted using Cre-expression in the germline; (ii) a congenic BL6 *Stxbp1*^+/−^ line; (iii) a reverse 129Sv *Stxbp1*^+/−^ line; and (iv) a *Gad2-Stxbp1^cre^*^/^*^+^* line. The *Stxbp1^cre^*^/^*^+^* line was created using *Cre-loxP*-mediated recombination in the germ line. *Cre-deleter* mice were crossed with *Stxbp1^+^*^/^*^lox^* mutants, which were generated on a C57BL/6J background ([@awy046-B34]) and bred further on C57BL/6J background, generating a *Stxbp1*^+/−^ mouse line without flanking gene variations. The congenic BL6 *Stxbp1*^+/−^ line was originally generated by deleting exons 2--6, preventing translation from amino acid 14 onwards, in the embryonic stem cells derived from a 129S1/SvImJ strain ([Fig. 4](#awy046-F4){ref-type="fig"}B; [@awy046-B73]) 20 years ago and back-crossed to C57BL/6J mice for \>40 generations. The reverse 129Sv *Stxbp1*^+/−^ line was created by mating male congenic BL6 *Stxbp1*^+/−^ mice with females of the inbred 129S1/SvImJ strain for three generations ([Fig. 4](#awy046-F4){ref-type="fig"}C). For the fourth mouse line, *Gad2-Stxbp1^cre^*^/^*^+^* mice, a selective heterozygous inactivation of *Stxbp1* expression in GABAergic cells was achieved by crossing Gad2TM2-Cre mice with *Stxbp1^+^*^/^*^lox^* mutants ([Fig. 4](#awy046-F4){ref-type="fig"}D). All these mice were viable and fertile, except the *Gad2-Stxbp1^cre^*^/^*^+^* mice where around 50% of the mice did not survive beyond postnatal Day 14 ([Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}, see below).

![**Generation, genomic analysis, routine behavioural observation and spontaneous activity of *Stxbp1*^+/−^ mice.** (**A--D**) Generations of four lines of *Stxbp1*^+/−^ mice: conditional, congenic BL6, reverse 129Sv and *Gad2*- *Stxbp1* line. Chromosomes bearing *Stxbp1* mutation originating from the C57BL/6J genetic background are shown in grey, and those from the 129/SvJ genetic background are shown in orange. *Stxbp1* mutation is represented with grey triangle; LoxP sites are represented with black rectangles and Cre-deleter lines are represented with scissors (red scissors: Cre expressed in all neuron, blue scissors: Gad2tm2-Cre mice with Cre-recombinase expressed in only GABAergic neurons). The flanking gene region is represented as orange region in the grey chromosome in the congenic BL6 line and vice versa in the reverse 129Sv line (adapted from [@awy046-B80]). (**E** and **F**) High-density genomic analysis showed the size and position of flanking gene region in *Stxbp1*^+/−^ samples from congenic BL6 and reverse 129Sv lines. 'Me-PaMuFind-It' web tool (<http://me-pamufind-it.org/>) revealed three genes with passenger mutations from 129Sv genetic background within flanking genes region in congenic BL6 *Stxbp1*^+/−^ samples. (**G**) *Stxbp1*^+/−^ mice showed lower body weight compared to their controls. (**H**) Grip strength was normal in *Stxbp1*^+/−^ mice. (**I**) Motor coordination and motor learning in *Stxbp1*^+/−^ mice was normal, as assessed on the rotarod. (**J** and **K**) Circadian rhythm assessed by changes in the activity in anticipation of (filled bars), and response to (open bars), day/night transitions and proportion of time spent outside the shelter was normal in *Stxbp1*^+/−^ mice. (**L**) Proportion of activity duration during the first 3 h of the dark phase days in the home-cage environment (PhenoTyper) showed increased activity of *Stxbp1*^+/−^ mice from all three lines during the first dark phase. (**M**) Proportion of activity duration in the PhenoTyper during the light phases was overall lower for *Stxbp1*^+/−^ mice (conditional mice, congenic BL6 and reverse 129Sv). The number of animals assigned is shown in the graphs. \**P \<*0.05; \*\*\**P \<*0.001.](awy046f4){#awy046-F4}

High-density genomic analysis revealed that after 40 generations, the 129/SvJ region flanking the *Stxbp1* locus extended \<10 Mbp upstream and downstream of the *Stxbp1* gene and contained 240 protein coding genes ([Fig. 4](#awy046-F4){ref-type="fig"}E). The 'Me-PaMuFind-It' web tool ([@awy046-B71]) identified 10 potential 129-derived passenger mutations in protein coding genes in the 129Sv/J-derived genomic region surrounding the *Stxbp1* gene. However, comparing the list of potential passenger mutations predicted by the 'Me-PaMuFind-It' web tool (see 'Material and methods' section) with the list of protein coding genes within the flanking gene region identified in our high-density genomic analysis we predict that three 129-derived passenger mutations are still present in our congenic BL6 mouse model: *Card9*, *Rapgef1* and *Dolpp1.* To our knowledge there is no evidence that these mutations are functional.

The high-density genomic analysis performed on the samples from the third generation of reverse 129/SvJ *Stxbp1*^+/−^ mice showed the expected percentage of residual genetic material from C57BL/6J background (for the third generation, the expected percentage was 12.5%, and 13.0 ± 2.7% was observed, *n* = 5); The C57BL/6J background genes were aggregated around previously detected flanking genes region of *Stxbp1* gene on the chromosome 2 ([Fig. 4](#awy046-F4){ref-type="fig"}F). Taken together, we derive the following conclusions regarding these mouse lines: (i) the *Stxbp1^cre^*^/^*^+^* line can be considered the most appropriate haploinsufficiency model on a C57BL/6J background, with no flanking gene issues. Its only imperfection is the presence of one remaining *LoxP* site; (ii) the congenic BL6 *Stxbp1*^+/−^ line can be exploited to test phenotypic effects of flanking genes (∼1% of the genome), a common problem for many behavioural studies using traditional knock-out mice ([@awy046-B21]; [@awy046-B80]; [@awy046-B71]); (iii) the reverse 129Sv *Stxbp1*^+/−^ line can be used to test differences in phenotypic expression of the same genotypes (*Stxbp1* heterozygosity), in different genomic backgrounds (C57BL/6J versus 129/SvJ); and (iv) the *Gad2-Stxbp1^cre^*^/^*^+^* can be used to specifically test phenotypic effects of *Stxbp1* heterozygosity in inhibitory neurons.

*Stxbp1* ^+/−^ mice show normal general behaviour
-------------------------------------------------

Eight-week-old *Stxbp1^cre^*^/^*^+^*, congenic BL6 *Stxbp1*^+/−^ and reverse 129Sv *Stxbp1*^+/−^ mice were viable and did not show overt phenotypic abnormalities. However, *Stxbp1*^+/−^ mice of all three lines showed a small but significant reduction in body weight at adulthood \[genotype: *F*(1,92) = 26.20, *P \<*0.001\] ([Fig. 4](#awy046-F4){ref-type="fig"}G). All three *Stxbp1*^+/−^ lines had similar muscle strength as assessed by the grip strength test at around 12 weeks of age and motor coordination tested on the rotarod at around 12 weeks of age ([Fig. 4](#awy046-F4){ref-type="fig"}H and I). The diurnal rhythm of *Stxbp1*^+/−^ mice was assessed by monitoring undisturbed behaviour in an automated home-cage system (PhenoTyper) enriched with a shelter for three consecutive days. It has been described before that mice tend to sleep/rest inside the shelter and they spend time outside the shelter during the active period ([@awy046-B46]; [@awy046-B43]). The change of activity in anticipation of and response to light/dark transitions and the changes in the time spent outside the shelter in the PhenoTyper were similar between genotypes ([Fig. 4](#awy046-F4){ref-type="fig"}J and K), except for increased activity in response to dark phase observed for reverse 129Sv *Stxbp1*^+/−^ mouse lines (*P \<*0.001). Taken together, our data suggest that besides the slightly lower body weight, there were no general abnormalities in motor performance, spontaneous activity and diurnal behaviour in *Stxbp1*^+/−^ mouse lines.

*Stxbp1* haploinsufficiency influences spontaneous activity
-----------------------------------------------------------

To assess spontaneous behaviour, we analysed a set of 115 behavioural parameters obtained after 3 days continuous video-monitoring in the PhenoTyper without human intervention. These parameters are divided in six main categories: activity, dark-light ratio, habituation, kinematics, sheltering, and phase transition ([@awy046-B43]). The analysis showed significant genotype effects mostly for activity and kinematics parameters in all *Stxbp1*^+/−^ mouse models ([Supplementary Tables 2--4](#sup1){ref-type="supplementary-material"}). Activity of all mice showed striking differences in relation to the time of the day, in particular during the first 3 h of the dark phase, the following 9 h of the dark phase and the light phase ([Fig. 4](#awy046-F4){ref-type="fig"}L, M and [Supplementary Fig. 6](#sup1){ref-type="supplementary-material"}). The activity of all *Stxbp1*^+/−^ mouse models was higher relative to control littermates during the first 3 h of the first dark phase in the PhenoTyper for all three lines \[genotype: *F*(1,176) = 35.25, *P \<*0.001; [Fig. 4](#awy046-F4){ref-type="fig"}L and [Supplementary Fig. 6](#sup1){ref-type="supplementary-material"}\], but not for the remaining 9 h of the dark phase ([Supplementary Fig. 6](#sup1){ref-type="supplementary-material"}). The reverse 129Sv line, but not the other lines, also showed increased activity during the first 3 h of the second and third dark phase (*P \<*0.001 and *P =*0.044, respectively; [Fig. 4](#awy046-F4){ref-type="fig"}L). Activity during the light phase was slightly lower when comparing *Stxbp1*^+/−^ mouse lines with their wild-type controls \[*F*(1,171) = 6.46, *P =*0.012; [Fig. 4](#awy046-F4){ref-type="fig"}M\]. In general, irrespective of *Stxbp1* genotype, the reverse 129Sv line mice had lower activity compared to congenic BL6 and *Stxbp1^cre^*^/^*^+^* mice ([Supplementary Tables 2--4](#sup1){ref-type="supplementary-material"}) as has been observed before [@awy046-B43]. Taken together, these data reveal an increased initial activity, probably in response to novelty, and a corresponding decreased activity during the subsequent light phase as a common feature of all *Stxbp1* mouse lines. For the 129Sv background, the increased activity during the initial hours of the dark phase was also observed on the subsequent 2 days.

*Stxbp1* ^+/−^ mice show epilepsy-like behaviour and EEG abnormalities that could be suppressed with levetiracetam
------------------------------------------------------------------------------------------------------------------

*STXBP1* haploinsufficiency in humans leads to epileptic spasms and tonic seizures, occurred mainly during sleep ([@awy046-B62]; [@awy046-B26]). To investigate similar phenotypes in *Stxbp1*^+/−^ mice, we performed video-monitoring of *Stxbp1*^+/−^ mice. These mice showed two types of the spontaneous abnormal behaviours: twitches ([Fig. 5](#awy046-F5){ref-type="fig"}A and [Supplementary Video 1](#sup2){ref-type="supplementary-material"}); and jumps ([Fig. 5](#awy046-F5){ref-type="fig"}B and [Supplementary Video 2](#sup3){ref-type="supplementary-material"}). These two types of events were observed when mice were in an inactive state (apparent sleep) and appeared to occur in a clustered pattern, but not strictly correlated ([Fig. 5](#awy046-F5){ref-type="fig"}C). Twitches and jumps were never observed in control littermates by two independent observers unaware of the genotype (*n* = 18, t = 4 h/animal). Twitches and jumps occurred predominantly, but not exclusively, during the light phase, the inactive phase of mice ([Fig. 5](#awy046-F5){ref-type="fig"}D). The average incidence of twitches and jumps was ∼1 twitch/h and ∼1 jump/1.5 h and was similar in the three genomic backgrounds tested, although twitches tended to be more frequent in the *Stxbp1^cre^*^/^*^+^* line ([Fig. 5](#awy046-F5){ref-type="fig"}E). Hence, abnormal motor activity in three *Stxbp1*^+/−^ mouse lines resemble tonic spasms and myoclonic jerks previously reported in human patients, also the fact that they occur predominantly during rest/sleep.

![**Video and EEG recordings revealed epileptic-like events in *Stxbp1*^+/−^ mice.** (**A**) Video monitoring revealed sudden jerks referred as twitches in *Stxbp1*^+/−^ mice. (**B**) Video monitoring revealed sudden jumps in *Stxbp1*^+/−^ mice, sometimes accompanied by Straub tail responses previously reported as a common phenomenon observed after seizure onset ([@awy046-B76]). (**C**) Distribution of motor effects of epileptic-like neural activity (twitches and jumps) during 3-h video-monitoring in *Stxbp1*^+/−^ mice from three lines: floxed, congenic BL6 and reverse 129Sv line. These motor events were never found in control mice (*Stxbp1^+^*^/^*^+^*). (**D**) Monitoring for 24 h showed that most of the twitches and jumps in congenic BL6 *Stxbp1*^+/−^ mouse occurred during the light phase (twitch: 22/34 and jump: 2/3) of the day/night cycle. (**E**) Average number of behavioural epileptic-like events per hour per line of *Stxbp1*^+/−^ mice. (**F**) Positions of the recording electrodes and ground electrode relative to Bregma. (**G**) Representative example of ECoG traces in a congenic BL6 *Stxbp1*^+/−^ mouse during the slow-wave sleep, awake state and spike-wave discharges. The red trace is an expanded ECoG trace of spike-wave discharge. (**H**) Power spectrum of slow wave sleep (SWS), spike wave discharge (SWD) and wake state. (**I**) Occurrence of behavioural epileptic events (twitches and jumps) and spike-wave discharges detected in cortical and hippocampal EEG traces during 3-h recording in *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice. (**J**) Predicted probability of coincidence of 3/13 twitches and 1/7 jumps with spike-wave discharge detected in a representative congenic BL6 *Stxbp1*^+/−^ mouse. Probability lower than 5% (grey line) was considered as concurrence. (**K**) Probability of concurrence of behavioural epileptic events and spike-wave discharges within 10 s presented as a negative logarithm for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice. (**L**) Total number of detected spike-wave discharges and epileptic events in the 12-h light phase. The number of mice: three *Stxbp1^cre^*^/^*^+^* mice, four congenic BL6 *Stxbp1*^+/−^ mice for cortical recording and two congenic BL6 *Stxbp1*^+/−^ mice for hippocampal recording. (**M**) Average frequency of detected spike-wave discharges during 6 h of recording after administration of saline, first levetiracetam dose (LEV I: 50 mg/kg, i.p.) and fifth levetiracetam dose (LEV V: 5 days, 50 mg/kg per day, i.p.). Different greyscale circles represent individual mice. \**P \<*0.05, \*\**P \<*0.01 compared to saline administration.](awy046f5){#awy046-F5}

To characterize the epileptic phenotype in *Stxbp1*^+/−^ mice further, we performed simultaneous video- and wireless EEG-monitoring in *Stxbp1*^+/−^ mouse models and controls. EEG electrodes were implanted in the hippocampal CA1 region (*n* = 2 BL6 *Stxbp1*^+/−^ and *n* = 2 control mice) or neocortex (*n* = 4 BL6 *Stxbp1*^+/−^, *n* = 3 *Stxbp1^cre^*^/^*^+^*, *n* = 4 control mice, [Fig. 5](#awy046-F5){ref-type="fig"}F). Both hippocampal and cortical recordings revealed frequent, high amplitude spike-wave discharges in all *Stxbp1*^+/−^ mice that were visually not detected in control mice ([Fig. 5](#awy046-F5){ref-type="fig"}G). The spike-wave discharges were characterized by high amplitude, low-voltage ECoG oscillations with a relatively narrow frequency band at ∼7 Hz, and duration usually between 1.5 and 2 s ([Fig. 5](#awy046-F5){ref-type="fig"}H). Spike-wave discharges were distinguished from slow-wave sleep by its clear peak at ∼7 Hz and from awake state or paradoxical sleep by larger amplitudes ([Fig. 5](#awy046-F5){ref-type="fig"}G and H).

Simultaneous video and wireless EEG-monitoring during the 12 h of the light phase revealed that some of the observed twitches and jumps ([Fig. 5](#awy046-F5){ref-type="fig"}A and B) coincided with spike-wave discharges ([Fig. 5](#awy046-F5){ref-type="fig"}I). To assess the strength of the correlation between behavioural and EEG events, we performed a simulation study. The probability that two types of events occurred within ±10 s by coincidence was far below 0.05 for twitches and around the limit of 0.05 for jumps ([Fig. 5](#awy046-F5){ref-type="fig"}J and K). Finally, the total number of events detected during the 12-h light phase was 49.4 ± 10.0, 17.6 ± 2.4 and 8.7 ± 1.2 for spike-wave discharges longer than 1.5 s, twitches, and jumps, respectively ([Fig. 5](#awy046-F5){ref-type="fig"}L). Comparison of spike-wave discharge incidence between *Stxbp1*^+/−^ mice and control littermates during 24 h recordings revealed that the total number of spike-wave discharge-like events is almost 100 times higher in *Stxbp1*^+/−^ mice (305 ± 54.5) as compared to control mice (5.6 ± 4.9, [Supplementary Fig. 5](#sup1){ref-type="supplementary-material"}). Together, these data show that the observed EEG/ECoG abnormalities were strongly correlated with twitches and a correlation with jumps was suggestive, but that not all spike-wave discharges detected in cortex and hippocampus resulted in behavioural manifestation and vice versa.

Levetiracetam is a commonly prescribed antiepileptic drug with a presynaptic mode of action binding to synaptic vesicle protein SV2A ([@awy046-B45]), and therefore, seems an excellent candidate to inhibit EEG abnormalities in the mouse models for disorders caused by mutations in the presynaptic gene *Stxbp1*. Acute treatment with levetiracetam significantly reduced the number of spike-wave discharges (*P =*0.004 compared to the saline treatment, [Fig. 5](#awy046-F5){ref-type="fig"}M). Prolonged levetiracetam treatment for 5 days had a similar effect as acute administration: a significant reduction of spike-wave discharges (*P =*0.036 compared to saline treatment, [Fig. 5](#awy046-F5){ref-type="fig"}M). Hence, levetiracetam effectively reduced ECoG abnormalities in *Stxbp1* mouse models.

The fourth mouse line, *Gad2-Stxbp1^cre^*^/^*^+^*, was not healthy enough for systematic analyses. Half the *Gad2-Stxbp1^cre^*^/^*^+^* mice died between the second and the third postnatal week, and the remaining animals showed strong epileptiform activity on ECoG, much more severe than the other three mouse lines ([Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). c-Fos expression was also increased much more than the other three mouse lines in several brain regions ([Supplementary Fig. 4](#sup1){ref-type="supplementary-material"}). For ethical reasons, these mice were sacrificed before further analyses could take place. Therefore, data obtained using this mouse line remain somewhat anecdotal. However, it is evident that *Stxbp1* heterozygosity in GABAergic neurons only, produced much stronger phenotypes than *Stxbp1* heterozygosity in all neurons.

Increased c-Fos expression in cortical regions of *Stxbp1*^+/−^ mice
--------------------------------------------------------------------

c-Fos is a well-established marker of neural activation. c-Fos levels can be rapidly (within 30--60 min) and transiently increased by diverse stimuli, including seizures ([@awy046-B35]). To study the pattern of c-Fos expression in *Stxbp1*^+/−^ mice, we performed c-Fos immunostaining of brain slices of congenic BL6 and *Stxbp1^cre^*^/^*^+^* mice and analysed c-Fos expression in 10 brain regions. Semi-quantitative analysis of c-Fos-positive cells showed increased c-Fos expression in prefrontal cortex, motor cortex and somatosensory cortex in both *Stxbp1* mouse models, but not in seven other regions ([Fig. 6](#awy046-F6){ref-type="fig"}A--S). Some variation in the localization of increased c-Fos expression was detected between the two mouse models and between individual mice. First, increased expression was detected in the prefrontal cortex of three congenic BL6 *Stxbp1*^+/−^ mice, but not in *Stxbp1^cre^*^/^*^+^* mice ([Fig. 6](#awy046-F6){ref-type="fig"}A--F). Second, increased expression in the motor cortex was detected in two *Stxbp1^cre^*^/^*^+^* and two congenic BL6 *Stxbp1*^+/−^, but not in the remaining mice ([Fig. 6](#awy046-F6){ref-type="fig"}G--L). Third, increased expression was detected in the somatosensory cortex of one *Stxbp1^cre^*^/^*^+^* and one congenic BL6 *Stxbp1*^+/−^ mouse, but not in the remaining mice ([Fig. 6](#awy046-F6){ref-type="fig"}M--R). These data indicate a robust increase of c-Fos expression in the specific brain regions. This increased expression was probably correlated to the recent seizure history.

![**c-Fos expression in *Stxbp1*^+/−^ mice.** (**A**--**R**) Representatives of c-Fos expression in prefrontal cortex (PFC), primary motor cortex (mCx) and somatosensory cortex (ssCx) for *Stxbp1^+^*^/^*^+^* mice (control), *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice. (**S**) Number of c-Fos positive cells per brain region for *Stxbp1^+^*^/^*^+^, Stxbp1^cre^*^/^*^+^*, and congenic BL6 *Stxbp1*^+/−^ mice. Scale bars and the number of samples are provided in the figure.](awy046f6){#awy046-F6}

*Stxbp1* haploinsufficiency affects behavioural flexibility but not spatial learning and attention in mice
----------------------------------------------------------------------------------------------------------

In addition to seizures, STXBP1-encephalopathies are characterized by additional symptoms, most notably cognitive deficits, developmental delay and autistic-like traits ([@awy046-B13]; [@awy046-B62]; [@awy046-B29]; [@awy046-B67]). Therefore, we tested multiple aspects of learning and memory, impulsivity and attention in *Stxbp1*^+/−^ mice. To evaluate spatial learning, memory and behavioural flexibility, we tested conditional and congenic BL6 mice in the Barnes maze, a dry and less stressful version of a spatial maze ([@awy046-B31]). Mice from reverse 129Sv line were tested in the Morris water maze instead, given their very low activity in the PhenoTyper and previously reported poor performance during the probe trial in the Barnes maze ([@awy046-B36]). To evaluate cognitive phenotypes in *Stxbp1*^+/−^ mice further, two automated cognitive tasks were performed in the PhenoTyper: the CognitionWall task for assessment of discrimination and reversal learning ([@awy046-B57]) and the Shelter task for assessment of avoidance learning ([@awy046-B46]). Additionally, attention and impulsivity were tested in the congenic BL6 line using the 5-choice serial reaction time task.

Spatial-learning paradigms showed that *Stxbp1*^+/−^ mice from all three lines have similar learning curves as their controls: a reduction in the escape latency and distance moved to reach the target with increasing number of training sessions ([Fig. 7](#awy046-F7){ref-type="fig"}A, B, E, F, G and H). Congenic BL6 *Stxbp1*^+/−^ mice showed a mild delay in the learning phase \[*F*(1,21) = 5.70, *P =*0.026; [Fig. 7](#awy046-F7){ref-type="fig"}A\] but tended to visit more holes in the target octant compared to control mice during the first probe trial \[*t*(21) = −1.80, *P =*0.086; [Fig. 7](#awy046-F7){ref-type="fig"}C and D\]. However, this mild delay in learning was not observed in the second cohort of congenic BL6 mice tested in the Barnes maze to analyse long-term memory, nor in the group tested in a novel version of the Barnes maze with increased complexity ([Supplementary Fig. 7](#sup1){ref-type="supplementary-material"}). Finally, reverse 129Sv *Stxbp1*^+/−^ mice also showed a normal learning curve in the Morris water maze ([Fig. 7](#awy046-F7){ref-type="fig"}G--I). Hence, these data suggest mild behavioural differences during the acquisition of spatial memory in *Stxbp1*^+/−^ mice, independent on the genetic background and paradigm used.

![**Learning and memory in *Stxbp1*^+/−^ mice in classical spatial paradigms and recently developed automated tasks in the PhenoTyper.** (**A** and **B**) Latency and distance travelled to find the escape hole in the Barnes maze during the learning phase for congenic BL6 *Stxbp1*^+/−^ mice. Congenic BL6 *Stxbp1*^+/−^ (HZ BL6) showed longer latency to find new escape hole during the learning phase (*P =*0.026) and during R1 (*P \<*0.001) and travelled longer distance to the new escape hole (R1-R3: *P =*0.024) compared to their controls (WT BL6). (**C**) HZ BL6 mice showed narrower distribution of holes visit around the target hole during the first probe trial (P1) compared to wild-type BL6. (**D**) Probability of hole visits in the old target octant during the P1 and P2 tended to be higher for HZ BL6 mice compared to their controls (*P =*0.086 and *P =*0.060, respectively) and there were no differences in the probability of hole visits in the new target octant during the P2. (**E** and **F**) Latency and distance travelled to find the escape hole in the Barnes maze during the learning phase were similar for *Stxbp1^cre^*^/^*^+^* mice (HZ cond) and their controls (wild-type cond). (**G** and **H**) Escape latency and distance travelled to the platform during the training in the Morris water maze was similar for reverse 129Sv *Stxbp1*^+/−^ mice and control mice. (**I**) Time spent per quadrant during the probe trial was similar for reverse 129Sv *Stxbp1*^+/−^ mice and control mice. (**J**) Schematic overview of the CognitionWall DL/RL task. (**K** and **L)** Kaplan-Meier survival curves shows the fraction of congenic BL6 and conditional *Stxbp1* mice that reached the 80% criterion as a function of hole entries during the DL and RL phases. (**M**) Average number of entries made per group to reach 80% criterion during the DL and RL phases. HZ BL6 mice reached the 80% criterion during RL with lower number of entries compared to control (*P =*0.004). (**N**) Schematic overview of the Shelter task protocol in the PhenoTyper to assess avoidance learning. (**O** and **P**) The preference index during the dark phases of the avoidance learning task was similar for HZ BL6 and HZ cond mice and their controls. *Insets* represent the learning effect on the preference index (D5/D6/D7-D4). The insets in graph **O** shows that congenic BL6 *Stxbp1*^+/−^ mice showed a stronger learning effect compared to their controls (*P =*0.012). (**Q** and **R**) The aversion index during the dark phases of avoidance learning task showed trend toward lower values for HZ BL6 mice compared to their controls (*P =*0.101). The aversion index was similar between HZ cond mice and their controls. \**P \<*0.05; \*\**P \<*0.01; \*\*\**P \<*0.001 compared to respective control. Statistical analysis is explained in the [Supplementary material](#sup1){ref-type="supplementary-material"}.](awy046f7){#awy046-F7}

After acquisition training sessions, reversal learning was tested by relocation of the target hole to the diametrically opposite side of the maze. Congenic BL6 *Stxbp1*^+/−^ mice showed significantly longer escape latency during the first reversal trial \[trial × genotype: *F*(1.583, 33.245) = 5.05, *P =*0.018, *post hoc* R1: *P \<*0.001; [Fig. 7](#awy046-F7){ref-type="fig"}A\] and longer distance travelled to the new target hole \[*F*(1,21) = 5.88, *P =*0.024; [Fig. 7](#awy046-F7){ref-type="fig"}B\]. During the second probe trial, congenic BL6 *Stxbp1*^+/−^ mice tended to visit more holes in the old target octant then control littermates \[*t*(21) = 1.98, *P =*0.060; [Fig. 7](#awy046-F7){ref-type="fig"}C and D\] and they showed the same probability of visiting holes in the new target octant as their controls \[*t*(21) = 1.15, *P =*0.264. [Fig. 7](#awy046-F7){ref-type="fig"}C and D\]. Additionally, during the third probe trial, performed after three additional reversal trials, no differences in the probability of holes visits were found between congenic BL6 *Stxbp1*^+/−^ mice and their controls \[*t*(21) = 0.93, *P =*0.364 [Supplementary Fig. 7A](#sup1){ref-type="supplementary-material"} and [B](#sup1){ref-type="supplementary-material"}\]. *Stxbp1^cre^*^/^*^+^* mice also showed a tendency to travel a longer distance than control littermates to find a new target hole during the first three reversal trials \[*F*(1,21) = 3.61, *P =*0.071 [Fig. 7](#awy046-F7){ref-type="fig"}F\]. Taken together, these data showed that *Stxbp1*^+/−^ mice were slower to reverse previously learned strategy, but did finally acquire/maintain the new strategy, suggesting impaired behavioural flexibility.

To explore discrimination and reversal learning further, a newly developed 4-day automated home-cage task was performed (CognitionWall test, [@awy046-B57]). This task uses an operant wall with three entry holes placed in the PhenoTyper in front of a reward dispenser ([Fig. 7](#awy046-F7){ref-type="fig"}J). During the first 2 days, mice had to learn to earn food rewards by passing through the left hole (discrimination learning) and during Days 3 and 4 the right hole was rewarded (reversal learning). During discrimination learning, *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice showed a similar distribution of entries made to reach the criterion of 80% correct entries as compared to control mice (*P =*0.952 and *P =*0.147, respectively; [Fig. 7](#awy046-F7){ref-type="fig"}K and M). During reversal learning, congenic BL6 *Stxbp1*^+/−^ mice made significantly fewer entries to reach the 80% criterion (*P =*0.004; [Fig. 7](#awy046-F7){ref-type="fig"}L and M), while *Stxbp1^cre^*^/^*^+^* mice required a similar number of entries as their controls (*P =*0.752; [Fig. 7](#awy046-F7){ref-type="fig"}L and M). Thus, congenic BL6 *Stxbp1*^+/−^ mice showed facilitated reversal learning in this test, while the *Stxbp1^cre^*^/^*^+^* mice showed normal performance.

To assess avoidance learning, the Shelter task ([@awy046-B46]), an automated PhenoTyper assay, was performed. In this test, avoidance learning is studied in an enriched home-cage with a shelter with two entrances, by first assessing the preferred entrance during the first 4 days in the cage of each individual mouse and subsequently applying an aversive stimulus (bright illumination) every time an animal enters the shelter through its preferred entrance ([Fig. 7](#awy046-F7){ref-type="fig"}N). The changes in the preference index (fraction of entries via the preferred entrance) were considered as a measure of cognitive response and the changes in the aversion index (a change in the time spent in now illuminated shelter) as the averseness of the bright illumination. *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice showed a decrease of preference index over days comparable with control mice \[genotype effect preference index: *F*(1,351) = 0.62, *P =*0.433; *F*(1,63) = 0.003, *P =*0.955, respectively, [Fig. 7](#awy046-F7){ref-type="fig"}O and P\]. However, the learning effect of congenic BL6 *Stxbp1*^+/−^ mice was significantly bigger compared to control mice during all three dark phases \[*F*(1,351) = 6.35, *P =*0.012; [Fig. 7](#awy046-F7){ref-type="fig"}O inset\]. Additionally, congenic BL6 *Stxbp1*^+/−^ mice showed a trend toward lower values of aversion index over days \[genotype: *F*(1,351) = 2.74, *P =*0.101; [Fig. 7](#awy046-F7){ref-type="fig"}Q\]. Reverse 129Sv *Stxbp1* mice were also tested in the Shelter task. However, these mice showed inconsistent behaviour ([Supplementary Fig. 8A](#sup1){ref-type="supplementary-material"}). Together, the Shelter task data indicate an enhanced cognitive response in congenic *BL6 Stxbp1*^+/−^ mice but a normal cognitive and aversive response in *Stxbp1^cre^*^/^*^+^* mice.

To assess the attentional capacity and impulsivity in congenic BL6 *Stxbp1* mice, the 5-choice serial reaction time task was performed. No significant effects of genotype on response accuracy, variability and omission errors (*P =*0.82, *P =*0.33 and *P =*0.68, respectively) and no differences in the number of impulsive responses (*P =*0.68; [Supplementary Fig. 7](#sup1){ref-type="supplementary-material"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}) were observed. Motivation to execute the task, as assessed by measuring the latency to a correct response and the reward latency were similar between congenic BL6 *Stxbp1*^+/−^ mice and their controls (*P =*0.63, *P =*0.12; [Supplementary Fig. 7](#sup1){ref-type="supplementary-material"} and [Supplementary Table 5](#sup1){ref-type="supplementary-material"}). Hence, attention performance and impulsivity was normal in congenic BL6 *Stxbp1*^+/−^ mice.

These cognitive tests suggest that *Stxbp1* haploinsufficiency impairs behavioural flexibility and promotes focused searching strategy in the Barnes maze in *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice, without affecting spatial learning in all three mouse models. The facilitated reversal learning and enhanced aversive cognitive response, accompanied with increased aversion in congenic BL6 *Stxbp1*^+/−^ mice, suggest a background-specific effect of *Stxbp1* haploinsufficiency in these behavioural domains. These background-specific effects were not explained by altered attention or impulsivity.

*Stxbp1* haploinsufficiency induces anxiety-like behaviour in mice and does not affect social behaviour
-------------------------------------------------------------------------------------------------------

Analysis of spontaneous behaviour during 3 days in the PhenoTyper revealed that *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice spent less time on top of the shelter compared to control mice (*P =*0.002 and *P \<*0.001, respectively; [Fig. 8](#awy046-F8){ref-type="fig"}A and B). As this parameter can be interpreted as index of anxiety-related behaviour, we tested anxiety more systematically in *Stxbp1*^+/−^ mouse models using well-established behavioural paradigms: the elevated plus maze, the dark-light box, the open field and novelty-induced hypophagia.

![**Anxiety-related phenotype and social behaviour in *Stxbp1*^+/−^ mice.** (**A**) Schematic overview of the PhenoTyper home-cage. (**B**) On shelter duration during the dark phase was shorter for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ (HZ cond and HZ BL6) mice compared to their controls. (**C--F**) Elevated plus maze (EPM) data. (**C**) Schematic overview of the EPM. (**D--F**) Latency to enter open arms was longer, time spent on the open arms and number of visits to the open arms were lower for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice compared to their controls. (**G--J**) Dark-light box (DLB) data. (**G**) Schematic overview of the DLB. (**H**) Latency to visit bright compartment (BC) was longer for congenic BL6 *Stxbp1*^+/−^ mice compared to their controls. (**I--J**) Time spent in the bright compartment and number of visits to the bright compartment was lower for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice compared to their controls. (**K--O**) Open field data. (**K**) Schematic overview of the open field. (**L**) Latency to visit centre zone was longer for *Stxbp1^cre^*^/^*^+^* and congenic BL- *Stxbp1*^+/−^ mice compared to their controls. (**M** and **N**) Percentage of distance moved in the centre zone and number of visits to centre zone was similar for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice and respective control mice. (**O**) The total distance moved was longer for reverse 129Sv *Stxbp1*^+/−^ mice compared to their control, and it was similar for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice and respective control mice. (**P** and **Q**) Novelty induced hypophagia test (NIHP) data. (**P**) Schematic overview of the NIHP test. (**Q**) Latency to consume highly palatable food (cracker) was similar for *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice and the respective controls. (**R**) Schematic overview of three-chamber test protocol. (**S**) During test for sociability (phase III), *Stxbp1^cre^*^/^*^+^*, congenic BL6 *Stxbp1*^+/−^ mice and their respective controls spent more time in the mouse zone than in the object containing zone. (**T**) During test for social novelty (phase IV), *Stxbp1^cre^*^/^*^+^*, congenic BL6 *Stxbp1*^+/−^ mice and their respective controls spent more time in the zone with novel mouse than in the zone with familiar mouse. There were no differences between genotypes. \**P \<*0.05, \*\**P \<*0.01, \*\*\**P \<*0.001 for comparison between zones.](awy046f8){#awy046-F8}

In the elevated plus maze ([Fig. 8](#awy046-F8){ref-type="fig"}C), *Stxbp1^cre^*^/^*^+^* and congenic Bl6-*Stxbp1*^+/−^ mice showed delayed latency to enter the open arms \[*F*(1,44) = 29.67, *P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}D\], spent less time on the open arms \[*F*(1,44) = 19.06, *P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}E\] and visited the open arms less frequently \[*F*(1,44) = 22.79, *P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}F\] compared to control mice. No differences were observed in total distance travelled between genotypes \[*F*(1,44) = 0.220, *P =*0.641\]. In the dark-light box test ([Fig. 8](#awy046-F8){ref-type="fig"}G), congenic BL6 *Stxbp1*^+/−^ mice showed longer latency to visit the bright compartment (*P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}H). Both *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice spent less time in the bright compartment (*P =*0.024 and *P \<*0.001, respectively; [Fig. 8](#awy046-F8){ref-type="fig"}I) and made fewer visits to the bright compartment \[*F*(1,44) = 53.68, *P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}J\] compared to control mice. In the open field test ([Fig. 8](#awy046-F8){ref-type="fig"}K), *Stxbp1^cre^*^/^*^+^*and congenic BL6 *Stxbp1*^+/−^ mice both showed a longer latency to visit the centre zone of the arena \[*F*(1,44) = 6.98, *P =*0.011; [Fig. 8](#awy046-F8){ref-type="fig"}L\] and showed a trend toward lower percentage of distance moved in the centre zone \[*F*(1,44) = 4.07, *P =*0.05; [Fig. 8](#awy046-F8){ref-type="fig"}M\], while making a similar number of visits to the centre zone \[*F*(1,44) = 2.04, *P =*0.160; [Fig. 8](#awy046-F8){ref-type="fig"}N\] and traveling similar total distance as control mice \[*F*(1,44) = 1.25, *P =*0.270; [Fig. 8](#awy046-F8){ref-type="fig"}O\]. We also tested how soon after being introduced into a novel home-cage, *Stxbp1*^+/−^ mice started to consume a familiar palatable piece of food (a cream cracker) to assess novelty-induced hypophagia ([Fig. 8](#awy046-F8){ref-type="fig"}P). This test showed a similar latency to eat between genotypes \[*F*(1,43) = 0.79, *P =*0.380; [Fig. 8](#awy046-F8){ref-type="fig"}Q\]. Analysis of anxiety-related behaviours using the same apparatuses and protocols as used for congenic BL6 and conditional lines was not possible for the reverse 129Sv line of *Stxbp1* mice due to the fact that the majority of mice, both *Stxbp1*^+/−^ and controls, did not visit anxiety-related compartments at all, as observed before (reviewed in [@awy046-B9]), and did not climb on the shelter in the PhenoTyper ([Supplementary Table 6](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 8B](#sup1){ref-type="supplementary-material"}). Altogether, these data indicate an increased anxiety-like behaviour in *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice that was not confounded by changes in motor activity.

Autism-related traits have been described in some STXBP1-encephalopathy patients ([@awy046-B50]; [@awy046-B5]). Therefore, we tested social behaviour of *Stxbp1* mouse models in the three-chamber test ([Fig. 8](#awy046-F8){ref-type="fig"}R). During the sociability phase, *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice, as well as their controls, spent significantly more time in the zone around an inverted mesh wire cup that contained a male conspecific compared to the time spent in the zone around an empty cup (conditional *Stxbp1^+^*^/^*^+^*: *P =*0.006, *Stxbp1^cre^*^/^*^+^*: *P \<*0.001, congenic BL6 *Stxbp1^+^*^/^*^+^*: *P \<*0.001, congenic BL6 *Stxbp1*^+/−^: *P =*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}S). Subsequently, a novel mouse was introduced in the previously empty cup and preference for social novelty was assessed. All tested animals, independent of the genotype and genetic background, spent significantly more time around the zone with the novel stimulus mouse (conditional *Stxbp1^+^*^/^*^+^*: *P =*0.020, *Stxbp1^cre^*^/^*^+^*: *P \<*0.001, congenic BL6 *Stxbp1^+^*^/^*^+^*: *P =*0.026, congenic BL6 *Stxbp1*^+/−^: *P \<*0.001; [Fig. 8](#awy046-F8){ref-type="fig"}T). Hence, *Stxbp1*^+/−^ mice with different genetic backgrounds show normal sociability and preference for social novelty.

Discussion
==========

In this study, *in vitro* experiments suggest that human disease-associated *STXBP1* mutations lead to decreased protein stability and consequently to reduced cellular protein levels and *Stxbp1*^+/−^ mice are presented as *in vivo* models for human STXBP1-encephalopathies. Haploinsufficiency of *Stxbp1* in mice recapitulated the STXBP1-phenotype observed in humans, with epileptic spasms, often during inactivity (sleep) and accompanied by slow wave discharges in the EEG/ECoG that were partially suppressed by the antiepileptic drug levetiracetam. These mouse models also showed impaired behavioural flexibility, but not impaired spatial learning, and an increased level of anxiety accompanied with hyperactivity. The latter two phenotypes have not yet been reported in patients. Finally, the present study demonstrates that the interplay between genetic background and *Stxbp1* dysfunction modulates the behavioural phenotype, leading to differences in cognitive traits depending on the genomic background.

Reduced protein stability and haploinsufficiency explain STXBP1-encephalopathy
------------------------------------------------------------------------------

When expressed on a null background, different disease-causing *STXBP1* variants supported synaptic transmission to different extents. These results are approximately as predicted. R388X and V84D are predicted to be highly disruptive, given the known loss of syntaxin-1 binding upon C-terminal deletions by R388X ([@awy046-B33]), while V84D adds a charge to a internally oriented residue ([@awy046-B51]). On the other hand, amino acid replacement with the same polarity/charge is predicted to have little effect, such as C180Y. Interestingly, this latter mutant was previously shown to be thermolabile *in vitro* and when expressed in non-neuronal cells ([@awy046-B47]), but supported normal synaptic transmission in primary neurons in this study (cultured at 37°C). Despite the very different support of synaptic transmission, patients have similar clinical symptoms and disease severity does not correlate with (predicted) disruptive capacity (reviewed by [@awy046-B67]). This lack of correlation between the extent of molecular functionality and clinical symptoms suggests that haploinsufficiency may explain STXBP1-encephalopathy. The fact that none of the disease-causing variants inhibited synaptic transmission when over-expressed on the heterozygous background excludes dominant-negative scenarios.

While the disruptive capacity of the different mutations is very different, all disease-causing variants are similar in having a markedly reduced stability in cells. This finding further supports haploinsufficiency as a plausible explanation for STXBP1-encephalopathy. The use of the 2A bi-cistronic ribosome-skipping approach ([@awy046-B60]) excludes reduced mRNA stability/half-life as an explanation for the markedly reduced cellular levels, because protein levels were quantified using the equimolar GFP expression. The reduced protein levels were detected in synapses, but also in somata, suggesting that reduced protein levels are not the consequence of 'late' local breakdown at synapses, by physiological mechanisms such a poly-ubiquitination, which has been reported for Munc18-1 ([@awy046-B47]; [@awy046-B65]). Instead, cellular levels of disease-causing variants appear to be reduced directly after biogenesis in the soma, except for one, M443R, which might have a synaptic targeting defect ([Fig. 1](#awy046-F1){ref-type="fig"}D and E). This might be caused by intrinsic differences in stability, such as thermo-instability ([@awy046-B61]; [@awy046-B47]) and/or by physiological quality control mechanisms. Interestingly, experimental mutations, which we have generated and tested in past studies, were often found to be expressed at normal levels, for instance S241A ([@awy046-B65]), L130K and F115E ([@awy046-B48]) and S306A/S313A ([@awy046-B79]) and physiological mechanisms of protein breakdown were implicated for mutations that showed lower cellular level, for instance S241D ([@awy046-B65]). Hence, disease-causing mutations share an unknown feature that experimental mutations do not show, that leads to their reduced cellular level, that cannot be explained by reduced mRNA stability and that seems to operate directly after biosynthesis, due to intrinsic stability differences and/or by cellular quality control.

Despite reduced stability, two disease-associated *STXBP1* variants, C180Y and C522R showed normal synaptic transmission on the null background. This is consistent with previous observations that a 50% reduced protein level does not lead to reduced (single) evoked responses ([@awy046-B68]). Cellular Munc18-1 levels in neurons expressing disease-causing variants are roughly 50% reduced ([Fig. 1](#awy046-F1){ref-type="fig"}D and E). Similarly, the normal (single) evoked responses when Munc18-1 levels are 50% reduced ([@awy046-B68]), also explains that all disease-causing variants showed normal (single) evoked responses when expressed on a heterozygous background ([Fig. 2](#awy046-F2){ref-type="fig"}). Thus synapses can support normal synaptic transmission with a single (wild-type) allele, at least for one to two responses ([@awy046-B68]). However, during more intense, repetitive stimulation, we previously showed that when Munc18-1 levels are 50% reduced, synapses show deeper rundown of synaptic responses (early fatigue) and that this rundown is more pronounced in GABAergic than in glutamatergic neurons ([@awy046-B68]). Such a differential effect in excitatory versus inhibitory synapses provides a plausible explanation for the epileptic traits observed in mice and humans with reduced neuronal Munc18-1 levels.

Cortical excitability imbalance explains epilepsy in STXBP1-encephalopathy
--------------------------------------------------------------------------

The epilepsy phenotype in STXBP1-encephalopathy patients is characterized with early onset infantile spasm, often during sleep, with focal and multifocal EEG activity in most patients and suppression-burst patterns in some patients ([@awy046-B61], [@awy046-B62]; [@awy046-B28]; [@awy046-B13]; [@awy046-B54]; [@awy046-B49]; [@awy046-B50]; [@awy046-B72]; [@awy046-B78]; [@awy046-B1]; [@awy046-B40]; [@awy046-B81]). The epilepsy-like phenotype in *Stxbp1*^+/−^ mice mimics these clinical features, with sudden myoclonic jerks (twitches), typically during rest (sleep) accompanied in some cases with spike-wave discharges that were suppressed by acute or prolonged levetiracetam treatment. The fact that correlation between behavioural manifestations and abnormal ECoG activity was not complete is compatible with the multifocal epileptic activity described in patients: some (correlated) events may not be detected with the single electrode used in our mouse studies. Interestingly, excessive neuronal activity was limited to different areas of the neocortex (motor-, somatosensory- and prefrontal-cortex) and was not observed in the hippocampus or lower brain areas. Hence, the neocortex might be the major source for seizure generation, at least in mouse models for STXBP1-encephalopathy.

The conclusion from our previous study that excitatory and inhibitory synapses are differentially affected by *Stxbp1* heterozygocity ([@awy046-B68], see also above), provides a plausible explanation for the epileptic traits observed in mice and humans with reduced neuronal Munc18-1 levels. The general information obtained from *Gad2- Stxbp1^cre^*^/^*^+^* mice suggests that these mice suffered from more severe and frequent seizures compared to pan-neuronal *Stxbp1*^+/−^ mice and abnormal ECoG activity. Taken together, these data suggest that imbalanced excitation in the neocortex, due to differentially affected excitatory and inhibitory neurotransmission ([@awy046-B68]) may explain the epilepsy features when one copy of the *Stxbp1* gene is mutated or inactivated.

Changes in presynaptic release machinery cause epilepsy and supports the 'synapthopathy' concept
------------------------------------------------------------------------------------------------

Mutations in several presynaptic genes, *STX1B*, *SNAP25*, *SYN1* and *SYN2*, cause epilepsy in mice and humans ([@awy046-B42]; [@awy046-B19]; [@awy046-B20]; [@awy046-B17]; [@awy046-B58]; [@awy046-B8]; [@awy046-B66]). The clinical features are rather different among these different forms of epilepsy. However, *Snap25*^S187A/S187A^ mice, showed similar spike-wave discharge patterns ([@awy046-B77]) as shown here for *Stxbp1* models. In contrast to *Stxbp1*^+/−^ mice, absence epilepsy and seizures in *Snap25*^S187A/S187A^ mice did not occur mainly during the inactive period (sleep) and electrographic epileptiform activity was not detected in the hippocampus ([@awy046-B10]; [@awy046-B53]). Furthermore, the antiepileptic drug, levetiracetam that binds the presynaptic protein SV2A and modulates synaptic transmission ([@awy046-B45]) is effective in two STXBP1-encephalopathy patients ([@awy046-B72]; [@awy046-B15]). Levetiracetam also suppresses ECoG abnormalities in *Stxbp1*^+/−^ mice. Hence, several lines of evidence suggest that changes in presynaptic proteins that regulate synaptic transmission produce epilepsy phenotypes, which can be alleviated by drugs that act presynaptically. This provides further support for the 'synaptopathy' model for some forms of epilepsy.

*Stxbp1* ^+/−^ mice show altered cognition and effect of the flanking genes on avoidance and late reversal learning
-------------------------------------------------------------------------------------------------------------------

Most patients with STXBP1-encephalopathy have severe intellectual disabilities and developmental delay (for a review see [@awy046-B67]). In *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice we observed an altered behavioural flexibility, but not altered spatial learning. In the Barnes maze, *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice were unable to suppress a previously learned strategy, suggesting impaired extinction component of behavioural flexibility. However, in the CognitionWall RL task, the congenic BL6 *Stxbp1*^+/−^ line performed better than control after 2 days of continued reversal learning. This suggests that reversal learning after prolonged training in the home-cage environment was in fact enhanced in the congenic BL6 *Stxbp1*^+/−^ line. Furthermore, the Shelter task suggested stronger avoidance learning and increased aversion in the same line. Higher aversion, improved avoidance learning and reversal learning after prolonged time in the home-cage in the congenic BL6 *Stxbp1*^+/−^ line, but not in *Stxbp1^cre^*^/^*^+^* mice, could be the consequence of Sv129-derived flanking genes expressed in the brain (especially *Rapgef1* and *Dolpp1*). Alternatively, it has been shown that stress can cause hyper-anxious state and either impair extinction or enhance the late phase of reversal learning, associated with alteration in the ventromedial prefrontal cortex ([@awy046-B6]; [@awy046-B14]; [@awy046-B23], [@awy046-B24]). Considering the increased anxiety observed in *Stxbp1^cre^*^/^*^+^* and congenic BL6 *Stxbp1*^+/−^ mice and excessive neural activity in prefrontal cortex detected selectively in congenic BL6 *Stxbp1*^+/−^ mice, we postulate that the neural mechanism similar to the stress-induced effect underlies altered behavioural flexibility in both *Stxbp1*^+/−^ lines and increased avoidance learning and facilitated reversal learning in congenic BL6 *Stxbp1*^+/−^. Taken together, our data on all *Stxbp1*^+/−^ lines show that these mouse models recapitulate deficit in domain of cognitive flexibility, but not spatial learning, i.e. a partial penetrance of the cognitive dimension of STXBP1-encephalopathy phenotype in mice.

*Stxbp1* ^+/−^ mouse models show hyperactivity and anxiety but not deficits in sociability
------------------------------------------------------------------------------------------

High prevalence of anxiety and autism spectrum disorders in epilepsy patients suggests that these disorders share underlying pathophysiology ([@awy046-B2]; [@awy046-B22]). In addition, mutations in several genes encoding synaptic proteins are implicated in both epilepsy and autism ([@awy046-B11]). A recent review ([@awy046-B67]) reports autistic features and other behavioural problems, such as hyperactivity in some patients with STXBP1-encephalopathy. *Stxbp1*^+/−^ mouse models show increased spontaneous motor activity and increased anxiety, but no impairment of sociability. Although *Stxbp1*^+/−^ mice showed normal circadian rhythm, they displayed increased motor activity in a novel environment during the dark phase and decreased activity during the light phase. On the other hand, motor activity of *Stxbp1*^+/−^ mice was normal in classical tests. This lack of effect may be due to the fact that all classical tests were performed during the light phase. Interestingly, hyperactivity has been previously reported in several mouse models of autism ([@awy046-B55]; [@awy046-B59]). *Stxbp1*^+/−^ mice display two phenotypic characteristics also relevant for autism: impaired behavioural flexibility and tendency towards more repetitive response (discussed above). On the other hand, *Stxbp1*^+/−^ mice did not show impairments in sociability, preference for social novelty, or enhanced motor learning as core elements of autistic behaviour ([@awy046-B59]). These data suggest that *Stxbp1*^+/−^ mice resemble an autistic phenotype in terms of hyperactivity and behavioural inflexibility but not the social-aspects of autistic behaviour.

Although it has been recognized that anxiety is a common comorbidity of epilepsy in patients ([@awy046-B2]), it has not been reported systematically in STXBP1-encephalopathy. However, *Stxbp1*^+/−^ mice showed robust anxiety-like phenotypes in several classical paradigms and also in the novel, automated tests in the home-cage. These data are in line with increased anxiety previously observed in S*txbp1*^+/−^ mice, measured by enhanced heart rate responsiveness ([@awy046-B27]). Our data are consistent with findings from other genetic mouse model of epilepsy, such as *Scn1a*^+/−^, *Snap25*^S187A/S187A^, *Arx*^(GCG)7/Y^, which report hyperactivity and anxiety as related neuropsychiatric comorbidities ([@awy046-B83]; [@awy046-B39]; [@awy046-B38]; [@awy046-B30]; [@awy046-B77]). In general, the reverse 129Sv model mice were hypoactive and showed high anxiety-related traits in accordance with previous studies ([@awy046-B37]; [@awy046-B9]). Similar to human behavioural data, the present study suggests that phenotypic spectrum of *Stxbp1*^+/−^ mice is broad and includes hyperactivity and anxiety.

Conclusion
==========

Together, the present study indicates that *Stxbp1*^+/−^ mice represent animal models with construct (same genetic cause of disease) and face (analogy with human symptoms) validity for STXBP1-encephalopathy. In addition, the effectivity of levetiracetam demonstrates predictive validity of *Stxbp1*^+/−^ mouse models for further therapy design. Protein instability due to disease-causing mutations in Munc18-1 and *Stxbp1* haploinsufficiency together explain STXBP1-encephalopathy, probably by imbalanced excitability in the neocortex, as suggested by increased c-Fos expression, and the previously observed enhanced synaptic fatigue, especially in GABAergic synapses ([@awy046-B68]), and strongly enhanced epilepsy traits in mice with single allele deletion of *Stxbp1* expression in GABAergic neurons. Finally, in addition to epileptic activity and cognitive phenotypes, *Stxbp1*^+/−^ mice showed increased anxiety, and hyperactivity, which has not been systematically reported in STXBP1-encephalopathy patients.
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Data are available at: <http://syli.cz/kovacevic>.
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ECoG

:   electrocorticography

EIEE

:   early infantile epileptic encephalopathy

EPSC

:   excitatory postsynaptic current
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